ReviewJournal of clinical medicine2021
Fibrin Clot Properties in Atherosclerotic Vascular Disease: From Pathophysiology to Clinical Outcomes.
Review in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 44 citations in OpenAlex.
- Homocysteine thiolactone contributes to the prognostic value of fibrin clot structure/function in coronary artery disease.PloS one · 2022Trial
- Effect of Perfluorooctanesulfonic Acid on Fibrin Clot Properties and Thrombin Generation: Linking Environmental Pollution with Cardiovascular Diseases.Journal of cardiovascular development and disease · 2026Article
- Review
- A lipid atlas of the human kidney.Science advances · 2025Article
- Use of Affimer technology for inhibition of α2-antiplasmin and enhancement of fibrinolysis.Blood advances · 2025Article
- Advanced Machine Learning to Predict Coronary Artery Disease Severity in Patients with Premature Myocardial Infarction.Reviews in cardiovascular medicine · 2025Article
- Carotid Stenosis and Stroke: Medicines, Stents, Surgery-"Wait-and-See" or Protect?Thrombosis and haemostasis · 2024Article
- Fibrin clot permeability (Ks) in patients on left ventricular assist device.Scientific reports · 2024Article
- Emerging Trends and Innovations in the Treatment and Diagnosis of Atherosclerosis and Cardiovascular Disease: A Comprehensive Review towards Healthier Aging.Pharmaceutics · 2024Review
- Neutrophil Extracellular Traps: A Crucial Factor in Post-Surgical Abdominal Adhesion Formation.Cells · 2024Review
- Association of Metallic and Nonmetallic Elements with Fibrin Clot Properties and Ischemic Stroke.Life (Basel, Switzerland) · 2024Article
- Fibrinolytic-deficiencies predispose hosts to septicemia from a catheter-associated UTI.Nature communications · 2024Article
- An up-to-date review of biomedical applications of serratiopeptidase and its biobetter derivatives as a multi-potential metalloprotease.Archives of microbiology · 2024Review
- Biomaterials in Drug Delivery: Advancements in Cancer and Diverse Therapies-Review.International journal of molecular sciences · 2024Review
- Changes in fibrin clot properties in patients after Roux-en-Y gastric bypass surgery.Research and practice in thrombosis and haemostasis · 2024Article
- Numerical modeling and analysis of cardiac stent using blood hammer principle.Technology and health care : official journal of the European Society for Engineering and Medicine · 2024Article
- GRSF1 antagonizes age-associated hypercoagulability via modulation of fibrinogen mRNA stability.Cell death & disease · 2023Article
- The Fibrinolytic System and Its Measurement: History, Current Uses and Future Directions for Diagnosis and Treatment.International journal of molecular sciences · 2023Review
- Fibrin clot properties in cardiovascular disease: from basic mechanisms to clinical practice.Cardiovascular research · 2023Review
- Circulating Biomarkers for Laboratory Diagnostics of Atherosclerosis-Literature Review.Diagnostics (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Fibrin is a major component of thrombi formed on the surface of atherosclerotic plaques. Fibrin accumulation as a consequence of local blood coagulation activation takes place inside atherosclerotic lesions and contributes to their growth. The imbalance between thrombin-mediated fibrin formation and fibrin degradation might enhance atherosclerosis in relation to inflammatory states reflected by increased fibrinogen concentrations, the key determinant of fibrin characteristics. There are large interindividual differences in fibrin clot structure and function measured in plasma-based assays and in purified fibrinogen-based systems. Several observational studies have demonstrated that subjects who tend to generate denser fibrin networks displaying impaired clot lysis are at an increased risk of developing advanced atherosclerosis and arterial thromboembolic events. Moreover, the majority of cardiovascular risk factors are also associated with unfavorably altered fibrin clot properties, with their improvement following effective therapy, in particular with aspirin, statins, and anticoagulant agents. The prothrombotic fibrin clot phenotype has been reported to have a predictive value in terms of myocardial infarction, ischemic stroke, and acute limb ischemia. This review article summarizes available data on the association of fibrin clot characteristics with atherosclerotic vascular disease and its potential practical implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.